Principal Investigator
Mikkael Sekeres
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20250345
Clinical Trial Summary
A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Leukemia/heme
Contact Information
Phone Number
305-243-2647